Back to top
more

Hepion Pharmaceuticals (HEPA)

(Delayed Data from NSDQ)

$0.65 USD

0.65
18,905

-0.01 (-1.38%)

Updated Nov 1, 2024 03:45 PM ET

After-Market: $0.63 -0.02 (-3.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 674.1% upside potential for Hepion Pharmaceuticals, Inc. (HEPA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days

by Zacks Equity Research

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.

Hepion Pharmaceuticals (HEPA) Jumps: Stock Rises 9%

by Zacks Equity Research

Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in Hepion (HEPA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Hepion (HEPA) stock based on the movements in the options market lately.

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

by Zacks Equity Research

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

by Zacks Equity Research

Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

Shrabana Mukherjee headshot

5 Stocks in Focus as Analysts Initiate Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

by Zacks Equity Research

Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

Shrabana Mukherjee headshot

Buy These 5 Stocks as New Analysts Initiate Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

by Sweta Killa

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Sweta Killa headshot

Biotech ETFs Surge on a Flurry of Positive News

by Sweta Killa

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.